St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
Location status: Recruiting
NCT Number: NCT06532474
In this observational study, researchers are looking at the effects of spinal muscular atrophy (SMA) drugs on the muscles and nerve cells in patients with SMA.
Primary Objectives
* To evaluate the feasibility and reliability of performing MR functional imaging in exercising muscle in patients with SMA. * To evaluate patients with SMA types 2 and 3 at baseline and longitudinally at 6 and 12 months
Secondary Objectives
* To describe the MR functional bioenergetics response in muscles in five potential groups of patients with spinal muscular atrophy: untreated, actively treated with nusinersen (Spinraza®) or onasemnogene abeparvovec (Zolgensma®), actively treated with risdiplam (Evrysdi®), switching from Spinraza or Zolgensma to Evrysdi and initiating combination therapy of Spinraza or Zolgensma with Evrysdi . * To identify changes in motor function in patients with SMA types 2 and 3 who initiate treatment with risdiplam. * To obtain biomarkers in blood, urine, and muscle tissue to provide proof-of-concept support for risdiplam effect on skeletal muscle. * To obtain quality of life and disability data from participants in this study.
Interested in participating?
Request Info5 year–20 year
All sexes
Observational
Memphis, Tennessee, 38105, United States
Location status: Recruiting
This is an observational study to demonstrate the feasibility of performing MR functional imaging in exercising muscle in patients with SMA. The participants will be prescribed medication by their treating physician, they will not receive any drug as part of this study.
Participants participating in the ML43225 study, will be put into groups depending on their type of SMA and the drugs they may or may not be taking. They will be asked to come to clinic 3 times over one year. Each visit will include magnetic resonance (MR) studies, a muscle ultrasound, a nerve test, muscle function testing, lung function testing, blood work, vital signs, and participants will be asked about their quality of life and daily life activities. After participants have completed the 3 required visits, they will be taken off study.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: At baseline and at 6 months (+/- 14 days)
MR functional imaging is considered feasible if ≥ 80% of MRI protocol eligible patients can complete 100% of imaging assessments at baseline and 6 months.
Time frame: At baseline and at 6 months (+/- 14 days)
MR functional imaging is considered reliable if the test-retest reliability is ≥ 0.80 for key imaging biomarkers.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Real-time 31P MR spectroscopy and CrCEST MRI will be used to measure phosphocreatine within the muscles at rest, during an exercise protocol, and during post-exercise recovery to baseline. Both measure the recovery time in seconds.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Real-time 31P MR spectroscopy and CrCEST MRI will be used to measure creatine concentrations within the muscles at rest, during an exercise protocol, and during post-exercise recovery to baseline. Both measure the recovery time in seconds.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Measurement of thickness of muscle compared to fat on MRI, measured in percentage.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Electrophysiological testing: Compound motor action potential (CMAP, measured in millivolts), motor unit number estimate (MUNE, average 200-400 for most limb muscles), and repetitive stimulation at 3 Hz - right ulnar to abductor digiti minimus and right fibular/peroneal nerve to tibialis anterior muscle.
A decrease of more than 40% in the amplitude of CMAP is considered abnormal.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
The Hammersmith Functional Motor Scale Expanded (HFMSE) has a score range from 0-66 with lower scores indicating poorer overall motor function.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
The Revised Upper Limb Module (RULM) has a score range 0-37 with lower scores indicating poorer upper limb motor function.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
The Block and Box Test (BBT) is a measure of gross manual dexterity and is scored by counting the number of blocks carried from one compartment to another. Higher scores are indicative of better manual dexterity.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
The 6-Minute Walk (6MW) Test measures how far someone can walk in six minutes, a higher score indicates better exercise tolerance score. A low score correlates with lower function.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
The 10 Meter Walk/Run (10MW) Test is measured in seconds and assesses walking speed over a short distance. Longer times indicate lower motor function
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
The 4-Stair Climb (4SC) Test is measured in seconds and assesses lower extremity power and motor function. Longer times indicate lower motor function
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
The Supine-to-Stand (STS) Test is measured in seconds and assesses the ability to move from laying on your back to standing up straight. Longer times indicate lower motor function.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
The Timed Up-and-Go (TUG) Test is measured in seconds and assesses the ability to stand up from sitting in a chair, walk 10 feet, turn around, walk back, and sit down. Longer times indicate lower motor function
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Myometry measures force in pounds or kilograms and measures the strength of a muscle group. The more force measured indicates more muscle strength.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Muscle thickness is measured in centimeters and echogenicity is measured in gray-scale value. Muscle thickness and echogenicity are related to muscle strength, physical function, muscle mass, and quality of muscle.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
The NF-L and pNF-H levels are measured in nanograms per milliliter from blood samples and can be an indicator of nerve cell damage. Higher values normally mean more nerve damage is occurring.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
SMN protein levels are measured in nanograms per milliliter from blood samples. Higher values indicate more SMN protein production which is normally deficit in people with SMA.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
This parameters has been added to better understand systemic glycolysis in this population in the context of measuring bioenergetics in muscle via fMRS. A normal blood pyruvic acid level is between 0.3 and 1.5 milligrams per deciliter (mg/dL). Elevated pyruvic acid in glycolysis usually indicates a disruption in the normal metabolic pathway.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
This parameter has been added to better understand systemic glycolysis in this population in the context of measuring bioenergetics in muscle via fMRS. Normally, blood lactate levels are between 1-2 mmol/L when not exercising. Elevated lactic acid during glycolysis indicates that the body is primarily relying on anaerobic glycolysis, meaning it is breaking down glucose for energy without sufficient oxygen, leading to a buildup of lactate as a byproduct.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
This parameters has been added to better understand systemic glycolysis in this population in the context of measuring bioenergetics in muscle via fMRS. Normal LDH levels in children vary by age. Normal adult range is 140-280 U/L. An elevated level of lactate dehydrogenase (LDH) in glycolysis indicates an increased rate of anaerobic metabolism.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Trough risdiplam drug level is measured in nanograms per milliliter from blood samples and indicates the concentration of risdiplam in someone's blood stream. Higher values mean someone has more risdiplam exposure.
This will only be tested on participants who are taking the drug risdiplam.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
The Pediatric Quality of Life Inventory (PedsQL) is a 23-item questionnaire measuring health-related quality of life in children and adolescents aged 2-18. Higher scores indicate better quality of life.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
The Pediatric Outcomes Data Collection Instrument (PODCI) is an 83-86 item questionnaire that measures the health-related quality of life for children and adolescents with musculoskeletal disorders aged 2-18. Higher scores indicate better quality of life.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
The SMA Health Index (SMA-HI) is a 107 item questionnaire that measures a patient's perception of disease burden in 15 areas of health related to SMA. Higher scores indicate more SMA disease burden
Contact information is provided by the study sponsor or research team.
St. Jude Children's Research Hospital
Other
Pilot Study Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed Therapies
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06955897
Behavior, Central Nervous System Diseases
New York, United States
View Trial DetailsNCT07047144
Anti-myostatin, Central Nervous System Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT07444476
Central Nervous System Diseases, Motor Neuron Disease
Norfolk, Virginia, United States
View Trial DetailsNCT05866419
Bone Diseases, Central Nervous System Diseases
Phoenix, Arizona, United States
View Trial Details